Search

Your search keyword '"Yin, Xia"' showing total 275 results
Start Over Author "Yin, Xia" Publisher elsevier bv
275 results on '"Yin, Xia"'

3. Lung tumor discrimination by deep neural network model CanDo via DNA methylation in bronchial lavage

Author

Yu, Zezhong, primary, Li, Jieyi, additional, Deng, Yi, additional, Li, Chun, additional, Ye, Maosong, additional, Zhang, Yong, additional, Huang, Yuqing, additional, Wang, Xintao, additional, Zhao, Xiaokai, additional, Liu, Jie, additional, Liu, Zilong, additional, Yin, Xia, additional, Mei, Lijiang, additional, Hou, Yingyong, additional, Hu, Qin, additional, Huang, Yao, additional, Wang, Rongping, additional, Fu, Huiyu, additional, Qiu, Rumeng, additional, Xu, Jiahuan, additional, Gong, Ziying, additional, Zhang, Daoyun, additional, and Zhang, Xin, additional

Published
2024
Full Text
View/download PDF

31. Contact optimisation strategy for wafer-scale field-effect transistors based on two-dimensional semiconductors

Author

Ling Tong, Xiaojiao Guo, Zhangfeng Shen, Lihui Zhou, Jingyi Ma, Xinyu Chen, Honglei Chen, Yin Xia, Chuming Sheng, Saifei Gou, Die Wang, Xinyu Wang, Xiangqi Dong, Yuxuan Zhu, Xinzhi Zhang, David Wei Zhang, Sheng Dai, Xi Li, Peng Zhou, Yangang Wang, and Wenzhong Bao

Subjects
Polymers and Plastics, Mechanics of Materials, Mechanical Engineering, Materials Chemistry, Metals and Alloys, Ceramics and Composites
Published
2023

32. Functional redundancy among Polycomb complexes in maintaining the pluripotent state of embryonic stem cells

Author

Yaru Zhu, Lixia Dong, Congcong Wang, Kunying Hao, Jingnan Wang, Linchun Zhao, Lijun Xu, Yin Xia, Qing Jiang, and Jinzhong Qin

Subjects
Polycomb Repressive Complex 1, Polycomb Repressive Complex 2, Genetics, Drosophila Proteins, Polycomb-Group Proteins, Cell Differentiation, Cell Biology, Biochemistry, Embryonic Stem Cells, Developmental Biology
Abstract

Polycomb group proteins assemble into multi-protein complexes, known as Polycomb repressive complexes 1 and 2 (PRC1 and PRC2), that guide cell fate decisions during embryonic development. PRC1 forms an array of biochemically distinct canonical PRC1 (cPRC1) or non-canonical PRC1 (ncPRC1) complexes characterized by the mutually exclusive presence of PCGF (PCGF1-PCGF6) paralog subunit; however, whether each one of these subcomplexes fulfills a distinct role remains largely controversial. Here, by performing a CRISPR-based loss-of-function screen in embryonic stem cells (ESCs), we uncovered a previously unappreciated functional redundancy among PRC1 subcomplexes. Disruption of ncPRC1, but not cPRC1, displayed severe defects in ESC pluripotency. Remarkably, coablation of non-canonical and canonical PRC1 in ESCs resulted in exacerbation of the phenotype observed in the non-canonical PRC1-null ESCs, highlighting the importance of functional redundancy among PRC1 subcomplexes. Together, our studies demonstrate that PRC1 subcomplexes act redundantly to silence lineage-specific genes and ensure robust maintenance of ESC identity.

Published
2022

33. Top gate engineering of field-effect transistors based on wafer-scale two-dimensional semiconductors

Author

Minxing Zhang, Lingyi Zong, Xinyu Wang, Wenzhong Bao, Xiaojiao Guo, Peng Zhou, Yin Wang, Yin Xia, Chen Luo, Chenjian Wu, Ling Tong, Jingyi Ma, Xinyu Chen, David Wei Zhang, Chuming Sheng, Saifei Gou, Xing Wu, and Yaochen Sheng

Subjects
Materials science, Polymers and Plastics, business.industry, Mechanical Engineering, Transistor, Metals and Alloys, Hardware_PERFORMANCEANDRELIABILITY, law.invention, Threshold voltage, Semiconductor, Mechanics of Materials, law, Logic gate, Hardware_INTEGRATEDCIRCUITS, Materials Chemistry, Ceramics and Composites, Inverter, Optoelectronics, Field-effect transistor, Wafer, business, Hardware_LOGICDESIGN, Voltage
Abstract

The investigation of two-dimensional (2D) materials has advanced into practical device applications, such as cascaded logic stages. However, incompatible electrical properties and inappropriate logic levels remain enormous challenges. In this work, a doping-free strategy is investigated by top gated (TG) MoS2 field-effect transistors (FETs) using various metal gates (Au, Cu, Ag, and Al). These metals with different work functions provide a convenient tuning knob for controlling threshold voltage (Vth) for MoS2 FETs. For instance, the Al electrode can create an extra electron doping (n-doping) behavior in the MoS2 TG-FETs due to a dipole effect at the gate-dielectric interface. In this work, by achieving matched electrical properties for the load transistor and the driver transistor in an inverter circuit, we successfully demonstrate wafer-scale MoS2 inverter arrays with an optimized inverter switching threshold voltage (VM) of 1.5 V and a DC voltage gain of 27 at a supply voltage (VDD) of 3 V. This work offers a novel scheme for the fabrication of fully integrated multistage logic circuits based on wafer-scale MoS2 film.

Published
2022

45. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation

Author

Yue Yin Xia, Jacek Gronwald, Beth Karlan, Jan Lubinski, Jeanna M. McCuaig, Jennifer Brooks, Pal Moller, Andrea Eisen, Sophie Sun, Leigha Senter, Louise Bordeleau, Susan L. Neuhausen, Christian F. Singer, Nadine Tung, William D. Foulkes, Ping Sun, Steven A. Narod, Joanne Kotsopoulos, Rinat Yerushalmi, Robert Fruscio, Antonella Rastelli, Stefania Zovato, Zerin Hyder, Tomasz Huzarski, Cezary Cybulski, Kevin Sweet, Marie Wood, Wendy McKinnon, Christine Elser, Tuya Pal, Georgia Wiesner, Eitan Friedman, Wendy Meschino, Carrie Snyder, Kelly Metcalfe, Aletta Poll, Nicole Gojska, Ellen Warner, Raymond H. Kim, Barry Rosen, Rochelle Demsky, Peter Ainsworth, Karen Panabaker, Linda Steele, Howard Saal, Kim Serfas, Seema Panchal, Carey A. Cullinane, Robert E. Reilly, Joanne L. Blum, Ava Kwong, Daniel Rayson, Claudine Isaacs, Teresa Ramón y Cajal, Jeffrey Dungan, Stephanie Cohen, Xia, Y, Gronwald, J, Karlan, B, Lubinski, J, Mccuaig, J, Brooks, J, Moller, P, Eisen, A, Sun, S, Senter, L, Bordeleau, L, Neuhausen, S, Singer, C, Tung, N, Foulkes, W, Sun, P, Narod, S, Kotsopoulos, J, Yerushalmi, R, Fruscio, R, Rastelli, A, Zovato, S, Hyder, Z, Huzarski, T, Cybulski, C, Sweet, K, Wood, M, Mckinnon, W, Elser, C, Pal, T, Wiesner, G, Friedman, E, Meschino, W, Snyder, C, Metcalfe, K, Poll, A, Gojska, N, Warner, E, Kim, R, Rosen, B, Demsky, R, Ainsworth, P, Panabaker, K, Steele, L, Saal, H, Serfas, K, Panchal, S, Cullinane, A, Reilly, R, Blum, J, Kwong, A, Rayson, D, Isaacs, C, Ramón y Cajal, T, Dungan, J, and Cohen, S

Subjects
BRCA2 Protein, Ovarian Neoplasms, Heterozygote, BRCA1 Protein, BRCA, Obstetrics and Gynecology, Breast Neoplasms, Carcinoma, Ovarian Epithelial, Case-control, Contraception, Oncology, Risk Factors, Ovarian cancer, Case-Control Studies, Mutation, Humans, Intrauterine device, Female, Contraceptives, Oral
Abstract

Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women with BRCA mutations. Methods A total of 1733 matched pairs were included in this analysis. Women were matched according to year of birth, date of study entry, country of residence, BRCA mutation type and history of breast cancer. Detailed information on hormonal, reproductive and lifestyle exposures were collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with each contraceptive exposure. Results Ever use of any contraceptive was significantly associated with reduced risk of ovarian cancer (OR = 0.62; 95% CI 0.52–0.75; P < 0.0001), which was driven by significant inverse associations with oral contraceptives (OR = 0.66; 95% CI 0.54–0.79; P < 0.0001) and contraceptive implants (OR = 0.30; 95% CI 0.12–0.73; P = 0.008). We observed a similar effect with use of injections (OR = 0.37; 95% CI 0.10–1.38; P = 0.14), but this did not achieve significance. No significant associations were observed between patterns of intrauterine device use and risk of ovarian cancer. Conclusions These findings support a protective effect of oral contraceptives and implants on risk of ovarian cancer among women with BRCA mutations. The possible protective effect of injections requires further evaluation.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results